Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role in the diagnosis of endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep5-2026a10006if. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

WHO Classification of Tumours Online https://tumourclassification.iarc.who.int/welcome/

The Cancer Genome Atlas Program (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations https://pubmed.ncbi.nlm.nih.gov/41967711/

Controversies in the Management of Serous Tubal Intra-Epithelial Carcinoma Lesions of the Fallopian Tube https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)00192-6/fulltext

Comparative Modeling of Recent and Projected Trends in the Incidence and Mortality of Uterine Cancer https://pubmed.ncbi.nlm.nih.gov/41643197/

Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal From the Italian Study Group https://pubmed.ncbi.nlm.nih.gov/35463299/

Application of Artificial Intelligence in Gynecologic Cancers: A Bibliometric Analysis https://pubmed.ncbi.nlm.nih.gov/41585300/

Uterine Leiomyosarcoma https://pubmed.ncbi.nlm.nih.gov/35173990/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and Stephanie Lheureux discuss the importance of investigator-initiated clinical trials in endometrial cancer, research on carcinosarcoma, and ctDNA.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep4-2026a10006ie. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Advances in Antibody-Drug Conjugates for Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/40111079/

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

Translational Randomized Phase II Trial of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent, or Metastatic Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35288469/

Elucidating Divergent Biology in Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/40850250/

The Immune Microenvironment in Endometrial Carcinoma: Mechanisms and Therapeutic Targeting https://pubmed.ncbi.nlm.nih.gov/40746533/

Epithelial-Mesenchymal Transition Orchestrates Tumor Microenvironment: Current Perceptions and Challenges https://pubmed.ncbi.nlm.nih.gov/40176117/

Comparative Modeling of Recent and Projected Trends in the Incidence and Mortality of Uterine Cancer https://pubmed.ncbi.nlm.nih.gov/41643197/

Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39417689/

Targeting CDK2 for Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/40802510/

PYNNACLE Phase II Trial Assessing Rezatapopt (PC14586), a Selective p53 Reactivator, in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation https://www.gynecologiconcology-online.net/article/S0090-8258%2825%2900347-6/abstract

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula Matulonis and Jessica St. Laurent discuss endometrial cancer research, funding, early detection, and treatment, including the impact of GLP-1 receptor agonists.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep3-2026a10006id. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Hereditary Breast and Ovarian Cancer (HBOC): Review of Its Molecular Characteristics, Screening, Treatment, and Prognosis https://pubmed.ncbi.nlm.nih.gov/32862296/

Shifted Assembly and Function of mSWI/SNF Family Subcomplexes Underlie Targetable Dependencies in Dedifferentiated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/41116019/

Cancer Statistics, 2026 https://pubmed.ncbi.nlm.nih.gov/41528114/

Tirzepatide as an Innovative Treatment Strategy in a Pre-Clinical Model of Obesity-Driven Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39388742/

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38967919/

GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases https://pubmed.ncbi.nlm.nih.gov/41665904/

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome (SCREEN-CUP) https://clinicaltrials.gov/study/NCT07220239

Circulating Tumor DNA in Endometrial Cancer: Clinical Significance and Implications https://pubmed.ncbi.nlm.nih.gov/39955181/

PTEN Mutations as Predictive Marker for the High-Grade Endometrial Cancer Development in Slovak Women https://pubmed.ncbi.nlm.nih.gov/36592448/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.